News
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company May 06, 2025 3:30 AM ET ...
Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...
Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from ...
Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in a deal worth up to $415m. The agreement, ...
Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The collaboration agreement centres around Alchemab’s antibody discovery platform, ...
Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from ...
Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, ...
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire ...
CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from ...
Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results